Overview

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2020-06-19
Target enrollment:
Participant gender:
Summary
CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
Phase:
Phase 1
Details
Lead Sponsor:
DrugCendR Inc.
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel